SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-25-003211 to ELUTIA INC. (ELUT)

ELUTIA INC.
Date: March 25, 2025 · CIK: 0001708527 · Accession: 0000000000-25-003211

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-285870

Date
March 25, 2025
Author
Division of
Form
UPLOAD
Company
ELUTIA INC.

Letter

Re: Elutia, Inc. Registration Statement on Form S-3 Filed March 18, 2025 File No. 333-285870 Dear Matthew Ferguson:

March 25, 2025

Matthew Ferguson Chief Financial Officer Elutia, Inc. 12510 Prosperity Drive, Suite 370 Silver Spring, MD 20904

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Doris Stacey Gama at 202-551-3188 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: David Eaton, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 25, 2025

Matthew Ferguson
Chief Financial Officer
Elutia, Inc.
12510 Prosperity Drive, Suite 370
Silver Spring, MD 20904

 Re: Elutia, Inc.
 Registration Statement on Form S-3
 Filed March 18, 2025
 File No. 333-285870
Dear Matthew Ferguson:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Doris Stacey Gama at 202-551-3188 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: David Eaton, Esq.
</TEXT>
</DOCUMENT>